CD274 and non-small cell lung carcinoma: In this study, we showed that among patients with advanced-stage NSCLC and high PD-L1 expression, combination therapy with pembrolizumab and chemotherapy provided significantly better PFS, but not OS, than pembrolizumab monotherapy.